NCT03076112View on ClinicalTrials.gov

Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

PHASE3CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

April 25, 2017

Primary Completion Date

June 30, 2022

Study Completion Date

August 31, 2022

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Ipragliflozin

Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes

DRUG

Sitagliptin

Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes

Trial Locations (1)

463-707

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
collaborator

Astellas Pharma Korea, Inc.

INDUSTRY

lead

Seoul National University Bundang Hospital

OTHER

NCT03076112 - Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin | Biotech Hunter | Biotech Hunter